Vol. 2 No. 14: Immunomodulatory drugs: the foundation for treating hematological malignancies Amsterdam, 15 June 2006

Articles

• Introduction

  Meletios Dimopoulos

  https://doi.org/10.4081/hmr.v2i14.507

  Published: June 10, 2009

  136

  PDF: 102

  • PDF

• Improving treatment outcomes by understanding cytogenetics in myelodysplastic

  Aristotle Giagounidis

  https://doi.org/10.4081/hmr.v2i14.508

  Published: June 10, 2009

  163

  PDF: 324

  • PDF

• Transfusion independence and cytogenetic response in myelodysplastic syndromes. What this means for the patient

  Alan F. List

  https://doi.org/10.4081/hmr.v2i14.509

  Published: June 10, 2009

  178

  PDF: 516

  • PDF

• Prolonging time to progression and survival in relapsed/refractory multiple myeloma

  Pieter Sonneveld

  https://doi.org/10.4081/hmr.v2i14.510

  Published: June 10, 2009

  187

  PDF: 388

  • PDF

• Targeting the microenvironment: a new treatment paradigm for chronic lymphocytic leukaemia

  Asher Chanan-Khan

  https://doi.org/10.4081/hmr.v2i14.511

  Published: June 10, 2009

  164

  PDF: 426

  • PDF